These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 20580045

  • 1. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC, Ampil F, Burton G, Li BD, Chu QD.
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A, Chu QD, Panu L, Meschonat C, Caldito G, Lowery-Nordberg M, Li BD.
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.
    J Clin Oncol; 2008 May 10; 26(14):2373-8. PubMed ID: 18413639
    [Abstract] [Full Text] [Related]

  • 6. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY, Wang SS, Zhu MQ, Zheng L, Luo WB, Zhou ZM, Guan ZZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Jun 10; 30(6):456-61. PubMed ID: 19024523
    [Abstract] [Full Text] [Related]

  • 7. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D, Escrig-Sos J, Torrella-Ramos A, Alcalde-Sanchez M, Salvador-Sanchis JL.
    Breast; 2012 Jun 10; 21(3):401-5. PubMed ID: 22579462
    [Abstract] [Full Text] [Related]

  • 8. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C, Sutherland RL.
    J Clin Oncol; 2009 Oct 01; 27(28):4701-8. PubMed ID: 19720911
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
    Mizell J, Smith M, Li BD, Ampil F, Chu QD.
    Ann Surg Oncol; 2009 Oct 01; 16(10):2711-6. PubMed ID: 19593633
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ, Truong PT, Sadek BT, Alexander CS, Wiksyk B, Shenouda M, Raad RA, Taghian AG.
    Ann Surg Oncol; 2014 Oct 01; 21(11):3490-6. PubMed ID: 24841346
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2008 Mar 20; 26(9):1419-26. PubMed ID: 18285604
    [Abstract] [Full Text] [Related]

  • 16. Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients.
    Fitzal F, Riedl O, Wutzl L, Draxler W, Rudas M, Pluschnig U, Handl-Zeller L, Dubsky P, Bachleitner-Hofmann T, Steger G, Jakesz R, Gnant M.
    Breast Cancer Res Treat; 2007 May 20; 103(1):45-52. PubMed ID: 17417725
    [Abstract] [Full Text] [Related]

  • 17. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y, Guan Y, Zhao WH, Li Q, Xu BH.
    Zhonghua Zhong Liu Za Zhi; 2008 Dec 20; 30(12):917-20. PubMed ID: 19173993
    [Abstract] [Full Text] [Related]

  • 18. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C, Kestin L, Go N, Krauss D, Chen P, Goldstein N, Martinez A, Vicini FA.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1514-21. PubMed ID: 16005576
    [Abstract] [Full Text] [Related]

  • 19. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy.
    Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins GH, McNeese MD, Strom EA, Valero V, Hunt KK.
    Cancer; 2003 Feb 15; 97(4):926-33. PubMed ID: 12569592
    [Abstract] [Full Text] [Related]

  • 20. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.
    Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, O'Regan RM, Yu ES, Yu DS, Landry JC.
    Ann Surg Oncol; 2011 Oct 15; 18(10):2858-65. PubMed ID: 21442346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.